

EUROGIN 2013

HPV at a crossroads: 30 years of research and practice

**Florence, Italy
Nov. 3-6, 2013**

**Advanced program
(updated Sept 12, 2013, subject to change)**

Sunday, November 3

Main Training Course (MTC)

The main training course is designed to provide summaries of the most relevant knowledge on HPV infection and associated diseases with the aim of assisting physicians and educators. The topics covered range from the basic science fundamentals to emerging issues and the clinical uses of screening technologies, prophylactic HPV vaccines and extending to HPV-related diseases in external genitalia and head & neck.

Speakers will present only accepted evidence-based scientific information that has been published in the peer-reviewed medical literature.

8:30-10:00	MTC 1 – HPV infection and diseases: the global view Chair: S. Franceschi			Auditorium
	• The burden of HPV-associated diseases	S.	Franceschi	France
	• Epidemiology of HPV infection and related cancers – cervix vs. head & neck	L.	Alemany	Spain
	• Natural history: current knowledge and perspectives	N.	Wentzensen	USA
	• HPV life cycle – an overview	J.	Doorbar	UK
	• Discussion			

10:00 – 10:30 Coffee break

10:30-12:15	MTC 2 – Current standards for cervical cancer control - screening and vaccination, practices and challenges Chair: X. Bosch			Auditorium
	• HPV screening strategies: new evidence	J	Cuzick	UK
	• HPV screening: current and future perspectives	P.	Snijders	The Netherlands
	• HPV vaccines: update on efficacy, impact and safety profile	S.	Garland	Australia
	• HPV vaccines: implementation and experiences, strengths and weaknesses	P.-L.	Lopalco	Sweden
	• WHO HPV vaccines recommendations	S.	Wang	Switzerland
	• Discussion			

Oral Communications (OC)

Oral communications sessions are structured according to topics. Their program includes selected, original papers presented as short oral presentations.

8:30-10:00	OC 1 – Molecular markers Chair: P. Snijders			Sala Verde
10:30 - 12:15	OC 2 – Epidemiology 1 and pathogenesis of cervical and vulvar cancer Chair: A. Antilla			Sala Verde
8:30-10:00	OC 3 – Colposcopy Chair: J-C Boulanger – A. Perino			Limonaia
10:30 - 12:00	OC 4 – The clinical value of HPV testing in the management of cervical diseases Chair: P. Cristoforoni, A. Kaufmann			Limonaia

Practical Workshops (PWS)

The workshops are designed to meet leaders involved in cervical cancer prevention. These sessions enable the participants to share their experience with the experts and to better understand the missions, activities, experiences and perspectives of your organization program.

14:00-14:50	PWS 1 – HPV testing for decision-making in screening and management Chair: M. Arbyn			Auditorium
	• Age-specific screening strategies by settings and vaccination status	X.	Bosch	Spain
	• Management of HPV+ / cyto-negative women	C.	Meijer	The Netherlands
	• Management of ASCUS and LSIL women	M.	Einstein	USA
	• Evidence for clinical applications of HR HPV testing	M.	Arbyn	Belgium
	• Discussion			
14:50-15:35	PWS 2 – HPV vaccination: the critical issues and new developments Chair: A. Kreimer			Auditorium
	• Introduction	A.	Kreimer	USA
	• New issues and indications: their implications for optimal vaccine strategies	M.	Jit	UK
	• Cross-protection and alternating doses schedules	M.	Brisson	Canada
	• HPV infection in vaccinated young women	N.	Schlecht	USA
	• Discussion			

15:30 – 16:00 Coffee break

16:00-16:45	PWS 3 – Management of cervical diseases: translating research into practice Chair: T. Wright			Auditorium
	• How to optimize the risk management concept	T.	Wright	USA
	• Ablation vs. excision: how to make the right decision	M.	Sideri	Italy
	• New strategies for post-treatment surveillance	M.	Cruickshank	UK
	• Discussion			

16:45-17:30	PWS 4 – Announcing HPV infection: how to deal with the patient Chair: A.-B. Moscicki			Auditorium
	• Transmission: genital vs. oral – practical issues	M.	Goodman	USA
	• The risk of cervical cancer: what the patient should know	D.	Harper	USA
	• Announcing HPV+ results: the right messages and false ideas	A.-B.	Moscicki	USA
	• Discussion			

14:00 - 15:35	OC 5 – HPV Screening 1 Chair: D. Heideman,			Sala Verde
---------------	---	--	--	-------------------

16:00-17:30	OC 6 – Vaccines 1 Chair: B. Romanowski – M. Safaeian			Sala Verde
-------------	---	--	--	-------------------

WACC Forum & health education

Benefits and limitations of increasingly informed patients

Sharing knowledge and education for cervical cancer prevention

In parallel to EUROGIN 2013, the WACC Forum (November 3) is organized by the Women Against Cervical Cancer (WACC) Network which represents more than 50 associations from many different countries working for the benefit of women's health and involved in cervical cancer prevention.

This conference gathers players in the public health education sector from a number of countries, to share experiences on effective communication and learning tools aimed to increase HPV disease awareness and patient education towards active prevention.

12:15-13:30	WACC Forum Chairs: J. Smith, M. Steben			Limonaia
	• Lecture: results of a worldwide E-learning program on cervical cancer prevention	X.	Bosch	Spain
	• Educating women for HPV screening	D.	Harper	USA
	• Making clinical sense of the fauna of increasingly informed patients	M.	Steben	Canada
	• Advocacy, acceptability	F.	Martinon-Torres	Spain
	• Barriers to prevention	D.	Salisbury	UK
	• Cervical Cancer-Free Coalition: moving from evidence to action	J.	Smith	USA
13:30 – 15:45	OC 7 - WACC Forum Chairs: F. Martinon-Torres			Limonaia

WACC in Japan

(Jointly organized by PCAF (People's Campaign Against Female cancer) and the Japanese Expert Board for the Eradication of Cervical Cancer)

Aim:

To report and evaluate activities for Women Against Cervical Cancer in Japan in order to share experiences globally

16:00-17:30	WACC in Japan Chairs: N. Sakuragi, R. Konno, S. Garland			Limonaia
	<ul style="list-style-type: none">Recent trends in cervical cancer incidence and mortality in Japan	S.	Hanley	Japan
	<ul style="list-style-type: none">Women Against Cervical Cancer in Hokkaido: primary prevention			
	<ul style="list-style-type: none">- Surveys of attitudes towards HPV vaccination and importance of cancer education in schools	S.	Hanley	Japan
	<ul style="list-style-type: none">- PCAF's Shine campaign for publicizing current knowledge about cervical cancer	K.	Sakuragi	Japan
	<ul style="list-style-type: none">Women Against Cervical Cancer in Hokkaido: secondary and tertiary prevention			
	<ul style="list-style-type: none">- HPV testing in cervical cancer screening and function-preserving surgery in cervical cancer treatment	N.	Sakuragi	Japan
	<ul style="list-style-type: none">- Asparadise - patient support group for gynecologic cancer survivors	S.	Oshima	Japan
	<ul style="list-style-type: none">Activity of Japanese Expert Board for Eradication of Cervical Cancer for National immunization program and HPV screening	R.	Konno	Japan
	<ul style="list-style-type: none">Activity of Japan Cancer Society	H.	Konishi	Japan
	<ul style="list-style-type: none">Surveys of attitude for cervical cancer screening	M.	Ito	Japan
	<ul style="list-style-type: none">Local activities in Yokohama city	E.	Miyagi	Japan
	<ul style="list-style-type: none">Peer education for university students by Ribbon movement	A.	Namai	Japan
	<ul style="list-style-type: none">Discussion: Challenges in today and near future (All participants)			

Sunday, November 3 (cont'd)

19:00 – 20:30	Opening Ceremony			Auditorium
	Welcome messages			
	<ul style="list-style-type: none"> • Messages from the Presidents 	G. M.	Ronco Roy	Italy Canada
	<ul style="list-style-type: none"> • EUROGIN's contribution and proposals for the fight against HPV-associated diseases 	J.	Monsonogo	France
	<ul style="list-style-type: none"> • The worldwide expertise: the EUROGIN Roadmap contribution 	S.	Franceschi	France
	<ul style="list-style-type: none"> • The women's commitment: the WACC Foundation's efforts 	A. J.	Singer Smith	UK USA
	<ul style="list-style-type: none"> • Educational perspectives and translating research: the CME initiative 	J.	Cortes	Spain
	<ul style="list-style-type: none"> • The Italian experience 	F.	Carozzi	Italy
	<ul style="list-style-type: none"> • To the memory of Anne Szarewski 	J.	Cuzick	UK
	Opening Guest Lecture			
	<ul style="list-style-type: none"> • The squamocolumnar junction and cervical cancer prevention 	C.	Crum	USA

Monday, November 4

Main Scientific Sessions (MSS)

Main Scientific Sessions include keynote lectures providing a broad overview of the essential issues on cervical cancer prevention by the most prominent experts in their respective field.

8:00-9:30	MSS 1 – HPV Screening 1 revisited Chair: T. Cox - X. Bosch			Auditorium
	<ul style="list-style-type: none"> • Triage of women with negative cytology and positive high-risk HPV: an analysis of data from the SHENCCAST* II/III studies 	S.	Goodrich	USA
	<ul style="list-style-type: none"> • Cross-sectional and longitudinal data on the comparison of APTIMA and HC2 HPV assays in routine screening in Germany 	T.	Iftner	Germany
	<ul style="list-style-type: none"> • A prospective study of genotyping for the management of HPV-positive, Pap-negative results 	M.	Schiffman*	USA
	<ul style="list-style-type: none"> • Self-sample HPV-tests – effects in cervical cancer screening attendance in Finland 	A.	Virtanen	Finland
	<ul style="list-style-type: none"> • Implementing cervical cancer screening with HPV testing followed by Pap triage in routine practice: the Montreal VASCAR project 	K.	Louvanto	Canada
	<ul style="list-style-type: none"> • Risk of >CIN3 after 3 years of follow-up in the ATHENA Trial 	T	Wright	USA

9:30-11:00	MSS 2– Vaccines 1 Vaccination programs: lessons learned Chairs: P.-L. Lopalco, D. Salisbury			Auditorium
	<ul style="list-style-type: none"> • Decision-making process in introduction of HPV vaccination 	P.-L.	Lopalco	Sweden
	<ul style="list-style-type: none"> • Success stories in implementing HPV vaccination: the health economy issues 	D.	Salisbury	UK
	<ul style="list-style-type: none"> • Implementation of HPV vaccination for males: Australia’s experience so far 	J.	Brotherton	Australia
	<ul style="list-style-type: none"> • Regulatory aspects on HPV vaccine safety 	P.	Neels	Belgium
	<ul style="list-style-type: none"> • Lessons learned to date from HPV vaccination programs in developing countries 	S.	Wang	Switzerland
	<ul style="list-style-type: none"> • Discussion 			

11:00 – 11:30 Coffee break

8:00-9:30	OC 8 – Recent advances on anal HPV-related diseases Chair: L. Siproudhis – P. Mullerat			Sala Verde
------------------	---	--	--	-------------------

Scientific Session (SS)

The concurrent scientific sessions feature presentations of selected abstracts on new findings covering a broad range of topics related to genital cancer prevention and management of patients with HPV-associated diseases.

9:30-11:00	SS 1 – PREvention strategies for HPV-related Diseases In European CounTries (PREHDICT) Chairs: J. Dillner, C. Meijer			Sala Verde
	<ul style="list-style-type: none"> Quality assurance for cervical cancer screening in Europe 	M.	Elfström	Sweden
	<ul style="list-style-type: none"> Modeling the effect of vaccination on HPV infection prevention 			
	<ul style="list-style-type: none"> Modeling data about the effect of vaccination and screening on cancer prevention 	J.	Berkhof	The Netherlands
	<ul style="list-style-type: none"> New biomarkers in HPV screening 	P.	Snijders	The Netherlands
	<ul style="list-style-type: none"> Effect HPV screening on prevention of invasive cancer 	G.	Ronco	Italy
	<ul style="list-style-type: none"> Implementation policies and priority setting for the next years in EC countries: the CoheaHr project 	C.	Meijer	The Netherlands
8:30-11:00	SS 2 – Gynecologic Oncology: what is new in the treatment of cervix cancer? Chairs: C. Haie-Meder, S. Dexeus, T. Maggino			Limonaia
	<ul style="list-style-type: none"> Introduction 	C.	Haie-Meder	France
	<ul style="list-style-type: none"> What's new with positron emission tomography in cervical cancer 	G.	Bonardel	France
	<ul style="list-style-type: none"> Simple hysterectomy and sentinel node excision in cervical cancer 	M.	Roy	Canada
	<ul style="list-style-type: none"> New challenges in surgery of cervical cancers 	T.	Maggino	Italy
	<ul style="list-style-type: none"> Treatment of stages 1a and 2b of cervical cancers 	J.	Cortes	Spain
	<ul style="list-style-type: none"> Image-guided brachytherapy in cervical cancer 	R.	Pötter	Austria
	<ul style="list-style-type: none"> Radiotherapy and anti-HPV treatment 	E.	Deutsch	France
	<ul style="list-style-type: none"> Discussion 	M. T. S.	Roy Maggino Dexeus	Canada Italy Spain
8:00-11:00	OC 9 – HPV Epidemiology 2 Chair: I. Baussano – M. Goodman			Palazzo degli Affari (Gr. floor)

Clinical Sessions (CS)

The clinical sessions are designed to provide educational strategies and skill-building learning experiences and update of expertise for participants. The clinical sessions should enable participants to integrate in their everyday practice the basic and advanced principles of colposcopy as well as diagnosis and management of cervico-vaginal and vulvar diseases.

14:15-15:45	CS 1 – Screening 2 Molecular-based strategies for primary screening of cervical cancer Chairs: J. Dillner, A.-B. Moscicki			Auditorium
	<ul style="list-style-type: none"> Gain in protection of cervical cancer with HPV screening: new evidences 	G.	Ronco	Italy
	<ul style="list-style-type: none"> Risk-based screening strategies 	C.	Meijer	The Netherlands
	<ul style="list-style-type: none"> Benefits and harm of HPV-based screening 	A.	Antilla	Finland
	<ul style="list-style-type: none"> Existing strategies and innovative intervention: HPV alone vs. co-testing 	J.	Cuzick	UK
	<ul style="list-style-type: none"> Which test for which screening? 			
	<ul style="list-style-type: none"> - Pooled HPV DNA assays 	J.	Dillner	Sweden
	<ul style="list-style-type: none"> - HPV genotyping assays 	T.	Cox	USA
	<ul style="list-style-type: none"> - HPV mRNA assays 	M.	Arbyn	Belgium
	<ul style="list-style-type: none"> - careHPV 	A.	Longatto Filho	Brazil
	<ul style="list-style-type: none"> - p16 	F.	Carozzi	Italy
	<ul style="list-style-type: none"> - CINtec PLUS VUSA Screen 	C.	Meijer	The Netherlands
	<ul style="list-style-type: none"> Discussion 			
15:45-17:00	CS 2 – Vaccines 2 HPV vaccination: what's new? Chairs: J. Paavonen, M. Stanley			Auditorium
	<ul style="list-style-type: none"> Introduction: Current knowledge and the future 	M.	Stanley	UK
	<ul style="list-style-type: none"> Long-term registry-based follow-up 	J.	Dillner	Sweden
	<ul style="list-style-type: none"> HPV vaccination and gender equity: direct and indirect benefits of vaccination of males 	J.	Paavonen	Finland
	<ul style="list-style-type: none"> A community randomized phase IV vaccination trial on vaccination strategies: overview of deliverables 			
	<ul style="list-style-type: none"> Cost-benefits of HPV vaccination: new evidence 	N.	Van de Velde	Canada
	<ul style="list-style-type: none"> Discussion 			
14:15-16:00	TRAINING SESSION (H&N) – HPV and the clinic: state of the art in HPV head & neck squamous cell cancer (HNSCC) Chairs: H. Mehanna, J.-L. Lefebvre			Sala Verde
	<ul style="list-style-type: none"> Trends in the epidemiology and global burden of HPV+ and HPV- oropharyngeal cancer 	H.	Mehanna	UK
	<ul style="list-style-type: none"> Use of cell-based models to investigate the role of HPV infection in oropharyngeal carcinogenesis 	S.	Roberts	UK
	<ul style="list-style-type: none"> The combination of HPV and other biomarkers for prediction of clinical outcomes 	T.	Dalianis	Sweden
	<ul style="list-style-type: none"> Testing for HPV oropharyngeal cancer – pearls, 	P.	Snijders	The

	pitfalls and progress			Netherlands
	<ul style="list-style-type: none"> Clinical trials of treatment de-intensification in favorable risk HPV-associated head & neck cancer 	B.	Burtness	USA
	<ul style="list-style-type: none"> HPV associated oropharyngeal cancer – defining better treatment strategies 	D.	Rischin	Australia
	<ul style="list-style-type: none"> Prognostic effect and risk factors of HPV positivity in head & neck cancer 	J.-L.	Lefebvre	France
	<ul style="list-style-type: none"> Critical issues in selection of patients with oropharyngeal squamous cell carcinomas for treatment de-escalation trials 	R.	Brakenhoff	The Netherlands
	<ul style="list-style-type: none"> Discussion panel <ul style="list-style-type: none"> At which conditions will it be possible to modify the treatments? Designs to suggest for treatment trials of HNSCC according to HPV status 	J.	Lacau Saint Guily	France

16:00-17:00	SS 3 - (H&N) – Scientific panel discussion: HPV and tobacco interactions – how do we sort it out? Chairs: A. Chaturvedi, X. Castellsagué			Sala Verde
	<ul style="list-style-type: none"> Epidemiologic associations of smoking, HPV infection and related cancer 	S.	Franceschi	France
	<ul style="list-style-type: none"> Clinical aspects of HPV disease and smoking 	M.	Gillison	USA
	<ul style="list-style-type: none"> Molecular aspects of HPV and smoking in the carcinogenesis of head & neck cancers 	R.	Brakenhoff	The Netherlands
	<ul style="list-style-type: none"> Panel discussion on reasons for inconsistent associations in the literature and study designs/strategies for addressing the question 			

14:15-16:00	OC 10 – Screening and prevention, new developments Chair: M. Elfström – J.-J. Baldauf			Limonaia
--------------------	--	--	--	-----------------

16:00-17:30	OC 11 – HPV in men, emerging issues Chair: C. Pierce Campbell, C. Lacey			Limonaia
--------------------	--	--	--	-----------------

14:15-15:00	SS 4 – Quality assurance programs of HPV testing Chair: K. Cuschieri, E. Unger			Palazzo degli Affari (Gr. floor)
	<ul style="list-style-type: none"> Disagreement between HPV assays in primary screening 	J	Bonde	Denmark
	<ul style="list-style-type: none"> The evolving requirements for validation and QA of HPV tests for service 	K.	Cuschieri	UK
	<ul style="list-style-type: none"> API -Assay Performance Indicators; assessment and comparison of molecular HPV assay performance 	J.	Bonde	Denmark
	<ul style="list-style-type: none"> WHO HPV LabNet: Shared International Experience for Improved HPV Testing 	E.	Unger	USA
	<ul style="list-style-type: none"> Discussion 			

15:00-17:00	OC 12 – HPV testing – methods & value Chair: H. Cubie - J.-P. Bogers			Palazzo degli Affari (Gr. floor)
-------------	---	--	--	---

17:00 – 17:30 Coffee break

14:00 - 15:30	IW 1 - La comunicazione nell'era HPV Chairs: G. Amunni (ONS, ISPO, ITT), P. Bonanni (SITI) - Sessione in Italiano -			Palazzo degli Affari (1st floor)
	• Lettura magistrale	P.	Cristoforoni	Italy
	• La comunicazione nella campagne vaccinali	M.	Conversano	Italy
	• La comunicazione nello screening	C.	Cogo	Italy
	• La comunicazione con la popolazione	N.	Orthmann	Italy
	<u>Oral Communications (+3 submitted abstracts)</u>			
	• Discussione plenaria			

15:30-17:00	IW 2 - Malattie HPV correlate extra-cervicali Chairs: M. Barbero (SICPCV), P. Scirpa (SICPCV) - Sessione in Italiano -			Palazzo degli Affari (1st floor)
	• Lettura magistrale	M.	Tommasino	Italy
	• La vaccinazione nelle patologie extra-cervicali	P.	Castiglia	Italy
	• La malattia vulvare	C.	Carriero	Italy
	• La vaccinazione nel maschio	L.	Mariani	Italy
	• HPV e dermatologia	A.	Zuccati	Italy
	<u>Oral Communications (+ 3 submitted abstracts)</u>			
	• Discussione plenaria			

Tuesday, November 5

8:00-9:30	MSS 3 – HPV Screening 2 New evidence-based guidelines Chairs: E. Franco, T. Wright			Auditorium
	• Bias and pitfalls in cancer screening	E.	Franco	Canada
	• HPV-based screening guidelines in Europe	A.	Antilla	Finland
	• The US Preventive Services Task Force recommendations in cervical cancer screening	W.	Huh	USA
	• The ACS/ASCCP/ASCP guidelines in cervical cancer screening	T.	Wright	USA
	• The Canadian Task Force recommendations in cervical cancer screening	V.	Mai	Canada
	• Issues related to low resource settings			
	• Discussion			

9:30-11:00	MSS 4 – Cervical cancer control in Italy: screening and vaccination Chairs: F. Carozzi, A. Frega			Auditorium
	• Best practices in Italy to get a good vaccine coverage	P.	Bonanni	Italy Sweden
	Discussant:	P.-L.	Lopalco	
	• HPV as primary screening: from research to practice	M.	Zappa	Italy
	Discussant:	J.	Cuzick	UK

	<ul style="list-style-type: none"> The clinician : towards the change in prevention 	A.	Perino	Italy
	Discussant:	S.	Dexeus	Spain
	<ul style="list-style-type: none"> Discussion 			

8:00-9:30	MSS 5 - (H&N) – HPV and non-oropharyngeal cancers of the head & neck Chairs: M. Gillison			Sala Verde
	<ul style="list-style-type: none"> Introduction 	M.	Gillison	USA
	<ul style="list-style-type: none"> CDC data presentation 	M.	Goodman	USA
	<ul style="list-style-type: none"> IOC data presentation 	X.	Castellsagué	Spain
	<ul style="list-style-type: none"> Serology associations data 	M.	Pawlita	Germany
	<ul style="list-style-type: none"> Transcriptionally active HPV and the Barrett's metaplasia-dysplasia-adenocarcinoma sequence 	S.	Rajendra	Australia
	<ul style="list-style-type: none"> Discussion 			

9:30-11:00	SS 5 - (H&N) – HPV infection in the oral cavity: new insights Chairs: S. Syrjänen, T. Dalianis			Sala Verde
	<ul style="list-style-type: none"> Oral HPV infection: epidemiology, transmission and risk factors 	A.	Chaturvedi	USA
	<ul style="list-style-type: none"> Oral HPV: mechanisms of infection, persistence and natural history 	M.	Gillison	USA
	<ul style="list-style-type: none"> Genotype-specific incidence and clearance of human papillomavirus in oral mucosa of women: a six-year follow-up study 	S.	Syrjänen	Finland
	<ul style="list-style-type: none"> Oral HPV prevalence in youth in Sweden with and without voluntary vaccination 	T.	Dalianis	Sweden
	<ul style="list-style-type: none"> Why the tonsils are susceptible to HPV infection 	S.	Pai	USA
	<ul style="list-style-type: none"> Immune infiltration and hypoxia in oral-pharyngeal squamous carcinoma 	K.	Oguejiofor	USA
	<ul style="list-style-type: none"> Discussion 			

8:00-9:30	SS 6 – Vaccines 3 Recent advances on prophylactic HPV vaccination Chairs: S. Garland			Limonaia
	<ul style="list-style-type: none"> Overviews of HPV vaccination trials 			
	<ul style="list-style-type: none"> - FUTURE trial 	S.	Garland	Australia
	<ul style="list-style-type: none"> - PATRICIA trial 	J.	Paavonen	Finland
	<ul style="list-style-type: none"> - Costa Rica trial 	A.	Kreimer	USA
	<ul style="list-style-type: none"> Immunogenicity and efficacy of HPV vaccines based on fewer doses and administration 	M.	Safaeian	USA
	<ul style="list-style-type: none"> Do we need a new HPV vaccine? What the economic model can tell us 	M.	Jit	UK
	<ul style="list-style-type: none"> Discussion 			

9:30-11:00	SS 7 – New trends on vaginal self-sampling Chairs: A. Lorincz, J. Belinson			Limonaia
	<ul style="list-style-type: none"> Overview 	A.	Lorincz	UK
	<ul style="list-style-type: none"> Meta-analysis of the accuracy of HPV DNA testing using self-collected versus clinician-based sampling of cellular material to detect HG CIN 	M.	Arbyn	Belgium

	<ul style="list-style-type: none"> Self-sampling versus clinician sampling for use with the careHPV test 	A.	Lorincz	UK
	<ul style="list-style-type: none"> Self-sampling for non-attendees of screening in The Netherlands 	D.	Heideman	The Netherlands
	<ul style="list-style-type: none"> Mailed self-sampling intervention project among under-screened women in the United States 	A.	Des Marais	USA
	<ul style="list-style-type: none"> Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program 	E.	Östensson	Sweden
	<ul style="list-style-type: none"> Triage strategies for women who test HPV positive on self-sampled material: post-hoc analysis of the PROTECT-3A study 	V.	Verhoef	The Netherlands
	<ul style="list-style-type: none"> HPV infection and cervical lesions over 18 months in physician- and self-collected specimens in female sex workers, Kenya 	J.	Ting	USA
	<ul style="list-style-type: none"> Discussion 			

8:00 - 9:30	SS 8 – Late breakers Chair: S. Franceschi			Palazzo degli Affari (Gr. floor)
	<ul style="list-style-type: none"> Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in adolescent girls aged 10–14 years: 7-year follow-up. 	T.	Schwarz	Germany
	<ul style="list-style-type: none"> Comparison of long-term immunogenicity of two prophylactic human papillomavirus (HPV) vaccines: final analysis of a Phase III trial 	M.	Einstein	USA
	<ul style="list-style-type: none"> HPV Oncotect: a multi-study analysis 	P.	Karakitsos	USA
	<ul style="list-style-type: none"> An overview of the 9-valent HPV L1 virus-like particle vaccine clinical development program 	A.	Luxembourg	USA
	<ul style="list-style-type: none"> Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16- to 26-year-old women 	E.	Joura	Austria
	<ul style="list-style-type: none"> Immunogenicity and safety of a novel 9-valent HPV L1 virus-like particle vaccine in boys and girls 9-15 years old; comparison to women 16-26 years old 	P.	Van Damme	Belgium
	<ul style="list-style-type: none"> Immunogenicity and safety of a novel 9-valent HPV vaccine in girls 9-15 years of age compared to the quadrivalent vaccine 	P.	Van Damme	Belgium
	<ul style="list-style-type: none"> Safety and tolerability of a novel 9-valent HPV L1 virus-like particle vaccine in boys/girls age 9-15 and women age 16-26 	A.	Giuliano	USA

9:30 – 11:00	SS 9 – Therapeutic vaccines against HPV 16/18 infection – new developments Chair: D. Harper			Palazzo degli Affari (Gr. floor)
	<ul style="list-style-type: none"> Introduction: Prevention and treatment of human papillomavirus 16/18 related cervical diseases 	D.	Harper	USA
	<ul style="list-style-type: none"> Role of HPV screening and management of the HPV16/18-infected women 	X.	Bosch	Spain
	<ul style="list-style-type: none"> Biology of HPV infection and rationale 	M.	Stanley	

	for treatment prior occurrence of cervical lesions			
	<ul style="list-style-type: none"> Phase I trial results with ProCervix vaccine in HPV 16 / 18 infected women with normal cytology 	P.	Van Damme	
	<ul style="list-style-type: none"> Evolution of HPV testing in the wake of new therapeutic vaccines 	T.	Iftner	
	<ul style="list-style-type: none"> Closing Remarks 	D.	Harper	
8:00-9:30	OC 13 – Biology - Immunology Chair: M. Tommasino			Palazzo degli Affari Adua 1
9:30-11:00	SS 10 – Modeling Key issues in the field of HPV: how can models help our understanding? Chairs: M. Brisson, H. Berkhof			Palazzo degli Affari Adua 1
	<ul style="list-style-type: none"> Background 	M.	Brisson	Canada
	<ul style="list-style-type: none"> The interaction between HIV and HPV infections: how relevant is it for public health? 	M.-C.	Boily	UK
	<ul style="list-style-type: none"> Model validity and credible projections: an insight from PreHdict study 	I.	Baussano	France
	<ul style="list-style-type: none"> Serotype replacement: second-guessing the clustering of HPV types 	J.	Bogaards	The Netherlands
	<ul style="list-style-type: none"> HPV infections: herd effects following vaccination 	S.	Vänskä	Finland
	<ul style="list-style-type: none"> Inequalities in cervical cancer: role of vaccine herd immunity in protecting women with low screening participation 	T.	Malagon	Canada
	<ul style="list-style-type: none"> HPV vaccination in developing countries: assessing the value of vaccines across the world 	M.	Jit	UK
	<ul style="list-style-type: none"> Discussion 			
8:00-9:30	IW 3 - Vaccinazione e screening Chairs: E. Paci (ONS), S. Guaschino (SIMaST) - Sessione in Italiano -			Palazzo degli Affari (1st floor)
	<ul style="list-style-type: none"> Lettura magistrale 	S.	Franceschi	Italy
	<ul style="list-style-type: none"> Il punto di vista della sanità pubblica 	R.	Gasparini	Italy
	<ul style="list-style-type: none"> Il punto di vista dei programmi di screening 	P.	Giorgi-Rossi	Italy
	<ul style="list-style-type: none"> Il punto di vista del ginecologo 	A.	Ciavattini	Italy
	<u>Oral Communications (+ 3 submitted abstracts)</u>			
	<ul style="list-style-type: none"> Discussione plenaria 			
9:30-11:00	SS 11 – HPV genotyping, recent advances Chairs: S. De Sanjosé, J. Smith			Palazzo degli Affari (1st floor)
	<ul style="list-style-type: none"> Genotype distribution in penile and vulvar cancers within ICO studies 	L.	Alemanly	Spain
	<ul style="list-style-type: none"> The value of HPV genotyping in self-samples of screening non-attendees 	P.	Snijders	The Netherlands
	<ul style="list-style-type: none"> Differences in carcinogenicity of high-risk HPV types: inferences from cross-sectional meta-analyses 	G.	Clifford	France
	<ul style="list-style-type: none"> The distribution of 12 high-risk HPV types detected in high-grade CIN, VIN and VaIN lesions 	E.	Joura	Austria

	from women 16-45 years of age			
	<ul style="list-style-type: none"> HPV type distribution and age-specific incidence of external genital lesions in the HIM study 	D.	Ingles	USA
	<ul style="list-style-type: none"> Development and validation of a new HPV genotyping assay based on next generation sequencing 	J.	Belinson	USA
	<ul style="list-style-type: none"> Discussion 			

11:00 – 11:30 Coffee break

13:00-15:00	CS 3 – Performance of cervical colposcopy: a debate Chairs: J. Monsonego, A. Singer			Auditorium
	<ul style="list-style-type: none"> Applying the concept of equal risk=equal management to cervical colposcopy and biopsy? 	N.	Wentzensen	USA
	<ul style="list-style-type: none"> Accuracy of colposcopy - data from the FUTURE trial Discussant:	M. S.	Stoler Dexeus	USA Spain
	<ul style="list-style-type: none"> CIN2: reality or myth? Discussant:	A.- B. M.	Moscicki Sideri	USA Italy
	<ul style="list-style-type: none"> The value of random biopsies Discussant:	R. J.	Pretorius Bornstein	USA Israel
	<ul style="list-style-type: none"> New nomenclature by IFCPC Discussant:	J. A.	Bornstein Perino	Israel Italy
	<ul style="list-style-type: none"> Non-ablative treatment of CIN/VIN Discussant:	M. M.	Einstein Cruickshank	USA UK
	<ul style="list-style-type: none"> New methods of teaching colposcopy in the electronic age Discussant:	A. J.	Singer Cortes	UK Spain
	<ul style="list-style-type: none"> Quality control in colposcopy Discussant:	M. A.	Roy Singer	Canada UK

17:00 - 18:00	CS 4 – Clinical value of HPV testing Chairs: J. Cuzick, P. Snijders			Auditorium
	<ul style="list-style-type: none"> Effects of persistence and HPV type on the long-term risk of CIN3+ following HPV infection: 10 year follow-up of women in the artistic trial 	J.	Peto	UK
	<ul style="list-style-type: none"> Role of mRNA testing in triage of women with minor cytological abnormalities 	F.	Verdoort	Belgium
	<ul style="list-style-type: none"> 2012 consensus guidelines for the management of women with abnormal screening tests and CIN & AIS: a risk-based approach 	W.	Huh	USA
	<ul style="list-style-type: none"> Earlier detection of high-grade CIN and overdiagnosis with HPV vs. cytology 	G.	Ronco	Italy
	<ul style="list-style-type: none"> Discussion 			

18:00-19:15	SS 12– Update on HPV testing methods Chairs: T. Iftner, C. Clavel			Auditorium
	<ul style="list-style-type: none"> The Scottish Test of Cure Study (STOCS-H) – A multi-platform comparison of HPV tests in a post-treatment context 	H	Cubie	UK
	<ul style="list-style-type: none"> Comparison of HPV testing methods 	T.	Iftner	Germany

	<ul style="list-style-type: none"> • HPV testing in self-sampling 	A.	Kaufmann	Germany
	<ul style="list-style-type: none"> • Novel HPV testing methods 	M.	Poljak	Slovenia
	<ul style="list-style-type: none"> • Meta-Analyses on comparison of HPV tests for LSIL and ASCUS triage 	M.	Arbyn	Canada
	<ul style="list-style-type: none"> • Discussion 			
12:45 - 14:00	SS 13 - (H&N) – HPV and head & neck cancers: the key questions Chairs: J. Lacau Saint Guily, G. D’Souza			Sala Verde
	<ul style="list-style-type: none"> • HPV detection methods in head & neck cancers 	N.	Schlecht	USA
	<ul style="list-style-type: none"> • HPV in head & neck cancers epidemiology and impact on survival 	G.	D’Souza	UK
	<ul style="list-style-type: none"> • HPV effect on survival and treatment in head & neck cancers 	L.	Licitra	Italy
	<ul style="list-style-type: none"> • Why have HPV-positive OPC a more favorable prognosis? 	R.	Brakenhoff	The Netherlands
	<ul style="list-style-type: none"> • The case for vaccination of boys for oral HPV 	S.	Pai	USA
	<ul style="list-style-type: none"> • Tumor microenvironment in HPV+ squamous cell carcinoma of the head and neck 	C.	Badoual	France
	<ul style="list-style-type: none"> • Therapeutic vaccination for HPV OSCC 	S.	van der Burg	The Netherlands
	<ul style="list-style-type: none"> • Discussion 			
14:00-15:00	SEMINAR (H&N) – HPV infection and associated cancers: prevention and counseling Chairs: C. Fakhry, L. Licitra			Sala Verde
	<ul style="list-style-type: none"> • Considerations for prevention of HPV-driven HNC: HPV-related vaccination and promising biomarkers 	A.	Kreimer	USA
	<ul style="list-style-type: none"> • Considerations for potential methods of secondary prevention 	C.	Fakhry	USA
	<ul style="list-style-type: none"> • Common behavioral questions about oral HPV acquisition and transmission 	G.	D’Souza	UK
	<ul style="list-style-type: none"> • Key messages for media on HPV-related head & neck tumors 	L.	Licitra	Italy
	<ul style="list-style-type: none"> • Discussion 			
17:00-18:15	OC 14– HPV and head & neck cancers from research to practice 1 Chair: R. Brakenhoff			Sala Verde
18:15-19:30	OC 15 – HPV and head & neck cancers from research to practice 2 Chair: L. Licitra			Sala Verde
13:00-15:00	SS 14 – Low risk HPV infection and related diseases: the global picture Chairs: M. Steben, C. Lacey			Limonaia
	<ul style="list-style-type: none"> • LR vs. HR HPV infection – epidemiology – transmission 	A.	Giuliano	USA
	<ul style="list-style-type: none"> • Molecular biology 	J.	Doorbar	UK
	<ul style="list-style-type: none"> • Disease burden 	M.	Steben	Canada

	• The clinical picture	C.	Lacey	UK
	• Recurrent respiratory papillomatosis surveillance in Australia	J.	Brotherton	Australia
	• Management of LR HPV-associated diseases	P.	Mullerat	UK
	• Treatment of anal condyloma and recurrence	S.	Goldstone	USA
	• Discussion			

17:00-18:00	SS 15 – Therapeutic vaccines: looking into the future Chairs: M. Einstein, P. Stern			Limonaia
	• Immune responses from therapeutic vaccines for HPV-associated cancers	S.	van der Burg	The Netherlands
	• Therapeutic effect of the prophylactic HPV vaccines	A.	Kaufmann	Germany
	• Innovations in therapeutic vaccine development	M.	Safaeian	USA
	• Initial results of Vicoryx a phase I/IIa study of immunization with a p16INK4a derived peptide in patients with advanced HPV-associated cancers	M.	von Knebel Doeberitz	Germany
	• Discussion			

18:00-19:15	SS 16 – Anal HPV-associated diseases – the women's perspective Chairs: J. Palefsky, S. Goldstone			Limonaia
	• Anal HPV infection and anal neoplasia in HIV+ and HIV- women	J.	Palefsky	USA
	• Screening approaches for anal squamous intraepithelial lesions in women	P.	Mullerat	UK
	• Anal squamous intraepithelial lesions in HIV+ and HIV- women	A.	Grulich	Australia
	• Trends in anal cancer incidence in women and men	G.	Clifford	France
	• Current approaches to treatment of anal squamous intraepithelial lesions: a 13 years experience	S.	Goldstone	USA
	• Evolution of anal dysplasia lesions within human immunodeficiency virus positive patients screening.	L.	Siproudhis	France
	• Discussion			

13:00-15:00	SS 17 – Screening 3 Controversies in cervical cancer screening and prevention. Priority setting for cervical cancer control: developed vs. developing countries Chairs: N. Schlecht, M. Jit			Palazzo degli Affari (Gr. floor)
	Introduction: how to integrate screening and vaccination	X.	Bosch	Spain
	• Cytology vs. HPV testing - High income countries (HIC) - Low and middle income countries (LMIC)	C. J.	Meijer Smith	The Netherlands USA
	• Cervical HPV screening: self-testing vs. medical professional testing - High income countries (HIC) - Low income countries (LIC)	D. J.	Heideman Belinson	The Netherlands USA
	• 2 vs. 3 doses schedule - High income countries (HIC) - Low and middle income countries (LMIC)	M. R.	Brisson Sankarana	Canada France

			-rayanan	
	<ul style="list-style-type: none"> School vs. health center based delivery - High income countries (HIC) 	F.	Martinon-Torres	Spain
	<ul style="list-style-type: none"> - Low and middle income countries (LMIC) 	S.	Wang	Switzerland
	<ul style="list-style-type: none"> Improved screening vs. introduction of vaccination or both? 	H.	Berkhof	The Netherlands
	<ul style="list-style-type: none"> Discussion 			

17:00 - 19:15	SS 18 – Clinical value of p16 Chairs: M. von Knebel Doeberitz, C. Bergeron			Palazzo degli Affari (Gr. floor)
	<ul style="list-style-type: none"> Update on the pathogenesis of HPV-induced cervical lesions 	M.	von Knebel Doeberitz	Germany
	<ul style="list-style-type: none"> p16INK4a as novel diagnostic stratificator to define low and high grade lesions (the US perspective) 	M.	Stoler	USA
	<ul style="list-style-type: none"> Current evidence for using p16INK4a in histology and cytology: a systematic meta-analysis of published reports 	M. M.	Reuschenbach Arbyn	Germany Belgium
	<ul style="list-style-type: none"> Combined use of p16INK4a and Ki67 as biomarkers in primary cervical screening 	C.	Bergeron	France
	<ul style="list-style-type: none"> Combined use of p16INK4a and Ki67 as biomarkers in cytology: The US perspective 	N.	Wentzensen	USA
	<ul style="list-style-type: none"> The use of p16INK4a as triage tool for HPV-positive women 	G.	Ronco	Italy
	<ul style="list-style-type: none"> Discussion 			

13:00-15:00	SS 19 – HPV and other cancers, new insights Chairs: K. Syrjänen, M. Poljak			Palazzo degli Affari Adua 1
	<ul style="list-style-type: none"> HPV in head & neck cancer – epidemiology and impact on survival 	J.-L.	Lefebvre	France
	<ul style="list-style-type: none"> Lung cancer 	K.	Syrjänen	Finland
	<ul style="list-style-type: none"> Esophageal cancer: any role of HPV? 	M.	Poljak	Slovenia
	<ul style="list-style-type: none"> Breast cancer 	K.	Syrjänen	Finland
	<ul style="list-style-type: none"> Prostate cancer 	R.	Tachezy	Czech Rep.
	<ul style="list-style-type: none"> HPV and colorectal cancer: translating the molecular basis of the viral associated carcinogenesis in colorectal cancerous tissues 	L.	Lorenzon	Italy
	<ul style="list-style-type: none"> Penile cancer 	G.	Gross	Germany
	<ul style="list-style-type: none"> Discussion 			

17:00-18:00	SS 20 – Epigenetics of cervical carcinogenesis Chairs: C. Meijer, N. Wentzensen			Palazzo degli Affari Adua 1
	<ul style="list-style-type: none"> Methylation of the HPV genome, differences between HPV types 	N.	Wentzensen	USA
	<ul style="list-style-type: none"> Methylation analysis to improve cervical cancer screening 	B.	Wisman	The Netherlands
	<ul style="list-style-type: none"> Use of DNA methylation for screening of cervical and vaginal self-collected specimens 	R.	Steenbergen	The Netherlands
	<ul style="list-style-type: none"> Diagnostic classifiers based on HPV and human gene methylation 	A.	Lorincz	UK
	<ul style="list-style-type: none"> A DNA methylation signature that allows the triage of high-risk human papillomavirus DNA-positive 	M.	Schmitz	Germany

	women			
	• Discussion			

18:00-19:15	SS 21 – HPV infection: from molecular biology to diseases Chairs: J. Doorbar, K. Shroyer			Palazzo degli Affari Adua 1
	• Molecular basis of HPV persistency			
	• HPV latency at the cervix and other anatomic sites	A.B.	Moscicki	USA
	• Latency molecular explanations and HPV expression	J.	Doorbar	UK
	• Origins of cervical disease and biomarker selection	M.	Herfs	USA
	• Keratin 17 expression in cervical glandular and squamous neoplasia	K.	Shroyer	USA
	• Secondary alterations required for progression of early transformed lesion	M.	von Knebel Doeberitz	Germany
	• Discussion			

13:00-15:00	IW 4 - La prospettiva del laboratorio tra screening e vaccinazione Chairs: D. French (Gisci), G. Mojana (SICPCV) - Sessione in Italiano -			Palazzo degli Affari (1st floor)
	• Lezione magistrale	F.	Carozzi	Italy
	• La citologia di triage	M.	Confortini	Italy
	• Organizzazione di un laboratorio HPV di grandi dimensioni	M. T.	Sandri	Italy
	• Il type replacement : il ruolo del laboratorio	E.	Burroni	Italy
	<u>Oral Communications (+6 submitted abstracts)</u>			
	• Plenary discussion			

17:00 - 19:15	IW 5 - Protocollo di gestione nel follow-up post-trattamento e post colposcopia negativa Chairs: G. Amunni (ONS, ISPO, ITT), P. Giorgi- Rossi (Gisci) - Sessione in Italiano -			Palazzo degli Affari (1st floor)
	• Lezione magistrale	F.	Boselli	Italy
	• Il protocollo Gisci	T.	Maggino	Italy
	• Follow up con HPV test+ e Pap-	F.	Sopracordevole	Italy
	• Il punto di vista del ginecologo	C.	Penna	Italy
	• Presentazione di alcuni casi clinici	S.	Costa	Italy
	• Quale test HPV nel follow-up	A.	Del Mistro	Italy
	• Follow up del CIN I non trattato	C.A.	Liverani	Italy
	• Follow up dell' AIS trattato	P.	Cattani	Italy
	• Plenary discussion			
	<u>Oral Communications (+ 3 submitted abstracts)</u>			

Wednesday, November 6

8:00-9:30	CS 5 – Vaccines 4 HPV vaccination of patients with diseases Chair: E. Joura			Palazzo degli Affari (Gr. floor)
	<ul style="list-style-type: none"> • Effects of quadrivalent vaccine immunization in individual RRP patients 	T.	Fromm	Germany
	<ul style="list-style-type: none"> • Potential mechanisms of post-exposure prophylaxis by HPV vaccines 	A.	Kaufmann	Germany
	<ul style="list-style-type: none"> • Genital warts in males 	S.	Goldstone	USA
	<ul style="list-style-type: none"> • Reduction of recurrent diseases after conization 	E.	Joura	Austria
	<ul style="list-style-type: none"> • HPV types in recurrent diseases 	O.E.	Iversen	Norway
	<ul style="list-style-type: none"> • Discussion 			

9:30-11:00	MSS 6 – Epidemiology of HPV infection Chairs: M. Goodman, G. Clifford			Palazzo degli Affari (Gr. floor)
	<ul style="list-style-type: none"> • Sources of anogenital and oral HPV infection 	M.	Goodman	USA
	<ul style="list-style-type: none"> • Heterosexual transmission: results from a short term observational study 	A.- B.	Moscicki	USA
	<ul style="list-style-type: none"> • Worldwide variations in age-specific HPV prevalence curves: the driving role of sexual mixing 	I.	Baussano	France
	<ul style="list-style-type: none"> • Estimation of human papillomavirus (HPV) transmissibility: insights from mathematical modeling 	M.	Brisson	Canada
	<ul style="list-style-type: none"> • Lack of concordance between oral and cervical HPV infection among adult women in the USA: cross-sectional analysis of NHANES 2009-2010 	E.	Velasco	USA
	<ul style="list-style-type: none"> • Genital and reproductive health factors and HPV infection risk 	E.	Shaw	Canada
	<ul style="list-style-type: none"> • The impact of the 1965-1975 sexual revolution on female genital tract high-risk human papillomavirus prevalence in the United States 	A.	Rositch	USA
	<ul style="list-style-type: none"> • Discussion 			

11:00-12:30	MSS 7 - (H&N) – EUROGIN 2014 ROADMAP HPV infection in men, genito-anal vs. oral, convergences and divergences Chair: A. Giuliano			Palazzo degli Affari (Gr. floor)
	<ul style="list-style-type: none"> • Introduction: overview of HPV infection in men across anatomic sites and genital HPV natural history 	A.	Giuliano	USA
	<ul style="list-style-type: none"> • Anal HPV – men vs. women 	A.	Nyitray	USA
	<ul style="list-style-type: none"> • Oral HPV - men vs. women 	A.	Kreimer	USA
	<ul style="list-style-type: none"> • Compare transmission from male to female vs. female to male 	M.	Goodman	USA
	<ul style="list-style-type: none"> • HPV capsid antibody response – men vs. women 	B.	Lu	USA
	<ul style="list-style-type: none"> • Comparison of HPV-related disease in men and women 	S.	Franceschi	France
	<ul style="list-style-type: none"> • Discussion 			

12:30 – 14:00	OC 16 – HPV testing methods 2 Chair: A. Hesselink – H. Ikenberg			Palazzo degli Affari (Gr. floor)
8:00- 9:45	SS 22 – Vaccines 5 The post-vaccination era Chairs: J. Brotherton, P. Bonanni			Sala Verde
10'	• Human papillomavirus prevalence following a national vaccination program	S.	Tabrizi	Australia
10'	• Type replacement			
10'	• Reduction of cytologic atypia and cervical procedures	J.	Paavonen	Finland
10'	• Impact on screening participation	J.	Brotherton	Australia
10'	• Decline in CIN in Australia due to vaccination: results of a data linkage study	D.	Gertig	Australia
10'	• Evaluation of vaccine program effectiveness: a Nordic perspective	J.	Dillner	Sweden
10'	• Measures of vaccine effectiveness	S.	Garland	Australia
10'	• Comparison of Canadian and American systems in prevention	M.	Steben	Sweden
15'	• Discussion			
9:45- 11:15	SS 23 – Vaccines 6 Other potential indications and other targets for HPV vaccination Chairs: A. Grulich, X. Castellsagué			Sala Verde
	• Rationale to vaccinate males: - Genital - Anal	A. S.	Giuliano Goldstone	USA USA
	• Populations at risk of HPV diseases	J.	Palefsky	USA
	• Young adult women	X.	Castellsagué	Spain
	• Immunosuppressed patients	A.	Grulich	Australia
	• Vulnerable populations	S.	Garland	Australia
	• Discussion			
11:15- 13:00	OC 17 – Vaccines 2 –prophylactic and therapeutic vaccines Chair: P. Sparen – C. Sauvageau			Sala Verde
8:00- 9:30	CS 6 – Screening 4 Screening in various situations - are best practices linked to robust outcome data? Chairs: D. Harper, G. Ronco			Limonaia
	• Screening for special populations (I.S. – DES – History of CIN)	T.	Wright	USA
	• Screening of older women	D.	Harper	USA
	• Screening of vaccinated women	X.	Bosch	Spain
	• Screening following hysterectomy: is it relevant?	M.	Cruickshank	UK
	• Directions for research	E.	Franco	Canada
	• Discussion			
9:30- 11:15	OC 18 – Cyto-histology Chair: K. Syrjänen			Limonaia

11:15-12:45	CS 7 - Management Management options for women with HPV positive screening results Chairs: M. Stoler, W. Huh			Limonaia
	• Biomarkers for triage of HPV+ women	N.	Wentzensen	USA
	• Cytology	C.	Meijer	The Netherlands
	• Genotyping	M.	Stoler	USA
	• p16	C.	Bergeron	France
	• Reduction of colposcopy referrals through the use of screening tests and vaccination status	H.	Berkhof	The Netherlands
	• Discussion			

12:45-14:30	CS 8 – Advanced topics on colposcopy and treatment Chairs: J. Cortes, M. Roy			Limonaia
	• Risk of premature delivery after treatment of CIN: due to treatment or due to CIN?	M.	Cruickshank	UK
	• Adenocarcinoma in situ: diagnosis, treatment and follow-up	M.	Roy	Canada
	• HPV genotype mapping of high-grade CINs in three morphological zones of cone specimens	K.	Nielsen	Denmark
	• Colposcopic evaluation of HSIL cytology with negative hr-HPV tests rarely diagnoses endometrial cancer	R.	Pretorius	USA
	• SEMM device for treatment of high-grade intraepithelial lesions of the uterine cervix: Experience in a Brazilian university hospital	P.	Naud	Brazil
	• Evaluation of the clinical performance of the COBAS® 4800 HPV test in a colposcopy referred population	C.	White	Ireland
	• Surface distribution frequency and severity of cervical intraepithelial neoplasia in Chinese women	I.	Chang	USA
	• Proportion of excision and pregnancy outcomes after LLETZ for CIN	E.	Paraskevaidis	Greece
	• Outcomes of women with untreated CIN2 lesions: is there a role for HPV-related biomarkers?	M.	Kyrgiou	UK
	• A placebo-controlled phase 2B study of hexaminolevulinate photodynamic therapy in patients with CIN1 and CIN2	P.	Hillemanns	Germany
	• A Randomised Trial of Topical Treatment for Vulval Intraepithelial Neoplasia – Preliminary Clinical Results	A.	Tristram	UK

8:00-9:30	SS 24 – Cervical cancer control in low resource settings Chair: R. Sankaranarayanan			Onice
	• New WHO recommendations and guidelines to strengthen cervical cancer prevention and control			
	• Recent experiences on HPV vaccination in national immunization programs and scaling-up of cervical screening in developing countries	R.	Sankaranarayanan	France

	• GAVI HPV vaccine programme	T.	Cernuschi*	Switzerland
	• Management options for screen positive patients in developing countries	J.	Belinson	USA
	• HPV in HIV-high incidence areas	M.	Hutchko	
	• Different oncogenic HPV types in HIV positive than negative South African women with cervical cancer	M.C.	Van Aardt	South Africa
	• HPV Vaccination and cervical screening in Bhutan	U.	Tshomo	Bhutan
	• Discussion			

9:30-14:00	Advanced colposcopy course (Separate registration required – 100 €) Chair: A. Singer, N. Pisal			Onice
<p>This is a 6 hour intensive course conducted by 2 highly experienced colposcopists/oncologists. They will present the most up-to-date knowledge relating to colposcopy practice as well as of the management of the cervix and lower genital tract precancer. There will be lectures as well as a very informal interactive tutorial which will be clinically oriented. Topics will range from the basic (i.e. normal cervix) to advanced (i.e. micro-invasion and glandular disease). A CD (PDF format) of all PowerPoint lectures will be given out.</p>				
9:30	• Registration			
10:00	• The normal Cervix: a prerequisite to understanding the abnormal cervix	A.	Singer	UK
10:25	• How do we diagnose cervical precancer: pathology, HPV and biomarkers	A.	Singer	UK
11:00	• Questions and discussion			
11:10	• Coffee			
11:20	• The abnormal cervix: colposcopy and methods of examination and video case presentations	A. N.	Singer Pisal	UK UK
12:30	• Micro-invasive cancer and glandular disease: management	N.	Pisal	UK
12:55	• Treatment of cervical precancer: who, why and how	N.	Pisal	UK
13:35	• Coffee and cake			
13:45	• Interactive case presentations: cytology, colposcopy, pathology and treatment	A. N.	Singer Pisal	UK UK
15:00	• Summary and Close			